Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
The Healthereum Patient Behavior Management platform is a full cycle communication...
The Healthereum Patient Behavior Management pla...
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fiel...
Astellas Pharma Inc. is a pharmaceutical compan...
Enochian Biosciences is a pre-clinical stage biotechnology company committed to us...
Enochian Biosciences is a pre-clinical stage bi...
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading glo...
WuXi Biologics (stock code: 2269.HK), a Hong Ko...
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral ...
Evelo Biosciences, Inc. is a clinical stage bio...
CUTERA, Inc. was founded in 1998 and is a global provider of Face + Body laser, li...
CUTERA, Inc. was founded in 1998 and is a globa...
Compugen is a drug discovery company with a unique, broadly applicable, predictive...
Compugen is a drug discovery company with a uni...
Precision BioSciences is dedicated to improving life (DTIL) through its proprietar...
Precision BioSciences is dedicated to improving...
Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...
Celsion Corporation is a fully integrated bioph...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Join the National Investor Network and get the latest information with your interests in mind.